FAH Genotype

If you or your child have unexplained liver problems, a family history of a rare metabolic disorder, or were flagged on newborn screening for something called succinylacetone, this test answers a specific question: do you carry mutations in a gene that prevents your liver from finishing the breakdown of a common dietary amino acid? The gene is FAH (fumarylacetoacetate hydrolase), and when both copies carry harmful mutations, toxic byproducts build up in the liver, kidneys, and nervous system.

Tyrosinemia type 1, the disease this gene causes, was once almost universally fatal in early childhood. Treatment with a drug called nitisinone changed that, but only for people who are diagnosed in time. Knowing your FAH status is the difference between catching the disease before liver damage starts and discovering it after cirrhosis or liver cancer has already developed.

What This Gene Does

The FAH gene tells the body how to make fumarylacetoacetate hydrolase, an enzyme that performs the final step in breaking down tyrosine, an amino acid found in nearly every protein-containing food. When the enzyme is missing or broken because both copies of the FAH gene carry harmful mutations, the breakdown process stalls. Toxic intermediates, including a compound called succinylacetone, accumulate and poison liver and kidney cells.

This is an inherited recessive condition. You need two faulty copies of the gene, one from each parent, to develop the disease. People who carry just one faulty copy (called carriers) are typically healthy, but can pass the mutation to their children. The disease itself is called hereditary tyrosinemia type 1, sometimes abbreviated HT1 or TYRSN1.

Hereditary Tyrosinemia Type 1

When both FAH gene copies carry harmful mutations, the accumulated toxic byproducts damage the liver and kidneys, and trigger nerve crises that resemble porphyria attacks. Without treatment, children with the acute form develop liver failure in infancy. Even children who survive the acute phase face a high risk of liver cancer (hepatocellular carcinoma) in childhood if untreated.

The relationship between specific mutations and disease severity is not always straightforward. Studies of patients with confirmed FAH mutations have found that two people carrying the same mutations can have notably different clinical courses, ranging from severe infant-onset disease to milder, later-onset forms. One striking phenomenon is self-correction, where regenerating liver cells revert the mutation back to a working sequence, partly compensating for the inherited defect.

Hepatocellular Carcinoma Risk

Liver cancer is one of the most serious long-term threats for people with two faulty FAH copies. Even on nitisinone, the drug that stops the buildup of toxic intermediates, hepatocellular carcinoma can still develop, which is why ongoing liver imaging surveillance remains essential for anyone with confirmed disease. A case has been documented of a person who developed liver cirrhosis and hepatocellular carcinoma from a novel FAH variant despite having no elevation in standard tyrosine or succinylacetone screening markers, which means routine biochemical testing can miss atypical forms.

Cognitive and Neurological Effects

Even with modern treatment, children with confirmed FAH mutations and tyrosinemia type 1 can have cognitive differences from peers. A study comparing tyrosinemia type 1 patients with healthy controls found lower IQ, weaker executive function, and reduced social cognition. The authors concluded that IQ screening alone is not enough to monitor cognitive health in this population, and recommended broader neuropsychological assessment over time.

Population and Ancestry Differences

Different FAH mutations cluster in different populations, and the clinical meaning of a result depends partly on ancestry. In a survey of 29 tyrosinemia type 1 patients largely from Mediterranean countries, splicing mutations as a group accounted for about 70% of FAH gene alterations, with a single splice variant called IVS6-1(G>T) accounting for roughly 59% of alleles on its own. A stop mutation called W262X is a common cause in Finland. In French Canadian populations, a single splice mutation called IVS12+5G>A is so prevalent (accounting for nearly 88% of pathogenic variants) that population-wide carrier testing is feasible. Outside these populations, the spectrum of mutations is broader and more variable.

How This Test Differs From Newborn Screening

Most cases of tyrosinemia type 1 are first detected through newborn screening for succinylacetone, a byproduct that builds up when the FAH enzyme is missing. Newborn screening using succinylacetone has been shown to improve outcomes by enabling treatment before liver damage develops. However, screening can miss atypical or milder variants that produce less succinylacetone. A documented false-negative case showed that an infant with a milder FAH variant was missed by standard newborn screening because succinylacetone excretion was lower than the cutoff.

Direct FAH genetic testing answers a different question than the biochemical screen. The screen asks whether toxic byproducts are accumulating right now. The genetic test asks whether you carry mutations that could cause disease, in yourself or in future children. The two tests complement each other, and someone with an abnormal screen or unexplained liver disease benefits from confirming the diagnosis at the DNA level.

One Test, a Lifetime of Use

Your FAH genotype does not change. The DNA sequence in this gene is set at conception and stays the same in every cell of your body for the rest of your life. This is a one-time test that does not need to be repeated, except in the rare case where a confirmatory method is needed to verify an unexpected or uncertain result.

Where ongoing monitoring matters is in the phenotypes that follow from a confirmed diagnosis. If you have two harmful FAH variants, lifelong follow-up includes regular liver imaging to watch for hepatocellular carcinoma, blood tests to track succinylacetone and nitisinone drug levels, and kidney function monitoring. These companion tests are repeated frequently throughout life, even though the underlying genotype is fixed.

When Results Can Be Misleading

• Variant panel coverage: the test detects only the specific FAH mutations it is designed to find. A negative result rules out the variants included on the panel but does not rule out every possible mutation in the gene. If clinical suspicion is high and the panel is negative, full sequencing of the FAH gene may be warranted.
• Ancestry-specific frequencies: some mutations are common in one population (such as the IVS6-1 splice variant in Mediterranean cohorts, the IVS12+5G>A variant in French Canadians, or the W262X stop mutation in Finland) and very rare in others. The clinical meaning of a result, especially for carrier status, depends on your ancestry.
• Variants of uncertain significance: sequencing sometimes finds a change in the gene whose effect on the enzyme is not yet known. Discuss any uncertain variant with a genetics professional before making decisions.
• Genotype-phenotype variability: two people with the same FAH mutations can have different clinical courses. A genetic result tells you what variants you carry, not exactly how the disease will manifest.

Decision Pathway for an Abnormal Result

If testing finds two harmful FAH variants, the next step is to confirm the diagnosis with biochemical testing for succinylacetone and tyrosine, and to start care at a metabolic center with experience treating tyrosinemia. Standard management combines nitisinone with a tyrosine-restricted diet. Lifelong liver imaging surveillance for hepatocellular carcinoma is essential, even on treatment, since liver cancer has been documented in patients on nitisinone.

If testing finds one harmful variant, you are a carrier. Carriers are typically healthy but can pass the variant to children. If your partner is also a carrier, each child has a one-in-four chance of inheriting two variants and developing the disease. A genetic counselor can help you and biological family members understand reproductive options and decide whether siblings, parents, or children should also be tested.

If a variant of uncertain significance is reported, consider seeking a second opinion from a clinical geneticist and confirming with a different testing method. Functional studies of the specific variant, family segregation analysis, and biochemical testing can help clarify whether the change is actually harmful.